DarioHealth expands board with healthcare veteran Larry Leisure

NEW YORK - DarioHealth Corp. (NASDAQ:DRIO), a digital health company specializing in AI-driven chronic care management with a current market capitalization of $26.35 million, announced the addition of Lawrence B. Leisure to its Board of Directors. According to InvestingPro data, the company faces significant growth challenges, with revenue declining 2.09% in the last twelve months. Leisure, with a four-decade track record in healthcare and managed care, will contribute his extensive expertise to support Dario’s growth in the payer and employer markets.

Leisure’s career began in benefits consulting, leading to senior roles at prominent firms such as Towers Perrin and PricewaterhouseCoopers, and later at Accenture (NYSE:ACN). He has also held leadership positions at Kaiser Foundation Health Plan and UnitedHealth Group (NYSE:UNH)’s OptumInsight. His venture into healthcare investing included a stint as an Operating Partner at Kleiner Perkins and co-founding Chicago Pacific Founders, a private equity firm focused on healthcare.

The appointment is expected to leverage Leisure’s experience in health policy, reimbursement, and value-based care models, which aligns with Dario’s mission to deliver personalized care through its multi-chronic condition digital therapeutics platform. Dario’s platform provides data-driven, one-on-one coaching for conditions such as diabetes, hypertension, and behavioral health.

Erez Raphael, CEO of Dario, expressed confidence that Leisure’s deep healthcare industry knowledge and his commitment to healthcare innovation will be invaluable as Dario scales its solutions and strengthens its partnerships.

DarioHealth, known for its user-centric approach, aims to transform the management of chronic conditions by offering continuous care as opposed to traditional episodic healthcare. While maintaining a strong gross profit margin of 60.91%, InvestingPro analysis indicates the company is rapidly burning through cash. The company’s solutions have been well-received globally, catering to health plans, self-insured employers, care providers, and consumers.

This announcement contains forward-looking statements regarding Leisure’s potential impact on Dario’s expansion and the advancement of its AI-driven care platform. These forward-looking statements are subject to various factors that may influence Dario’s actual results. InvestingPro analysis suggests the stock is currently undervalued, though investors should note the company’s challenging financial metrics and high stock volatility. For deeper insights into DRIO’s valuation and growth prospects, access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.

The information in this article is based on a press release statement from DarioHealth Corp.

In other recent news, DarioHealth Corp announced a partnership with a Blue Cross Blue Shield health plan, integrating its AI-powered health coaching tools into the plan’s offerings. This collaboration, which began in January 2025, is anticipated to enhance DarioHealth’s annual recurring revenue in the first quarter of 2025. The agreement expands DarioHealth’s reach in the digital cardiometabolic care sector and marks its ninth collaboration with health plans. Meanwhile, TD Cowen downgraded DarioHealth’s stock rating from Buy to Hold, citing concerns over the company’s revenue growth trajectory and the extended timeline for reaching breakeven. The analyst noted limited investment and muted growth in the B2B2C segment as factors contributing to this outlook. Additionally, DarioHealth confirmed the election of six directors to its board and the ratification of its independent auditors at the 2024 Annual Meeting of Stockholders. The appointment of Kost Forer Gabbay & Kasierer as auditors was supported by a majority of votes. These developments are shaping the company’s strategic direction and financial expectations for the coming year.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.